Skip to content

Evaluation of A Statewide Program to Prevent Early Mortality and to Promote Fitness in Persons With SMI

Evaluation of A Statewide Program to Prevent Early Mortality and to Promote Fitness in Persons With SMI

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT02334280
Enrollment
120
Registered
2015-01-08
Start date
2009-09-30
Completion date
2013-05-31
Last updated
2015-01-08

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Bipolar Disorder, Schizoaffective Disorder, Schizophrenia

Keywords

Community mental health, Health coach, Weight loss, Fitness, Serious mental illness, Health promotion

Brief summary

The goal of this project, which has not changed, is to evaluate the statewide implementation of a two-component intervention (health promotion plus academic detailing) with respect to consumer outcomes and changes in provider prescribing. The intervention, called In SHAPE, is delivered to people with serious mental illness (SMI) by two community mental health clinics (CMHCs). These CMHCs are compared to two CMHCs delivering usual-care to individuals with SMI. The specific aims of this study are: 1. Evaluate person-level and provider-level outcomes including: (a) consumer health behaviors, health indicators, mental health indicators, and acute health service utilization, (b) provider prescribing practices and program fidelity, and (c) program costs. 2. Evaluate system-level outcomes including: (a) consumer health behaviors and health indicators, (b) provider prescribing and program fidelity, and (c) acute services use.

Detailed description

Individuals with SMI die 10-25 years earlier than the general population and have disproportionately greater rates of medical comorbidity and disability associated with high rates of obesity, sedentary lifestyle, metabolic syndrome, and poor dietary habits. Despite greater costs and adverse outcomes associated with the combination of mental illness and poor physical health, little attention has been paid to the development of health promotion interventions designed to address the needs of the high-risk group of people with SMI. This natural experiment presents an unprecedented opportunity to evaluate the public health impact of a statewide health-promotion program for persons with SMI, a potential model for reducing early mortality among persons with SMI served by state mental-health systems nationwide.

Interventions

BEHAVIORALIn SHAPE

In SHAPE is a health promotion intervention consisting of a fitness club membership and a health promotion coach with basic certification as a fitness trainer, instruction on principles of healthy eating and nutrition, and training in tailoring individual wellness plans to the needs of persons with serious mental illness.

Sponsors

Dartmouth-Hitchcock Medical Center
Lead SponsorOTHER

Study design

Allocation
NON_RANDOMIZED
Intervention model
PARALLEL
Primary purpose
HEALTH_SERVICES_RESEARCH
Masking
SINGLE (Outcomes Assessor)

Eligibility

Sex/Gender
ALL
Age
21 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Age 21 or older * Serious mental illness defined by (a) an axis I diagnosis of major depression, bipolar disorder, schizoaffective disorder, or schizophrenia, (b) moderate impairment across multiple areas of psychological functioning, or (c) Global Assessment of Functioning (GAF) score less than 61 * Able to provide voluntary informed consent for participation in the study by the participant or by the participant's legally designated guardian or conservator * Poor fitness as indicated by BMI \> 25 or failure to adhere to the US Department of Health and Human Services Physical Activity Guidelines for Americans, i.e., at least 2.5 hr/week of moderate or 75 min/week of vigorous activity in more than one session * Medical clearance for participation in an exercise and dietary modification program by a physician, physician assistant, or nurse practitioner * An expressed willingness to participate in a diet and exercise program * Currently taking an atypical antipsychotic medication * Able to walk a city block * Responsible for choice of foods and how they are prepared

Exclusion criteria

* Currently residing in a nursing home or group home * Terminal physical illness expected to result in the death of the study subject within one year * Primary diagnosis of dementia, co-morbid diagnosis of dementia, or significant cognitive impairment as indicated by a Mini-Mental State Examination (MMSE) score \< 24 * Inability to speak and understand English * Pregnancy

Design outcomes

Primary

MeasureTime frameDescription
Change in exercise capacitybaseline, 6-, 12-, and 24-monthsChange in exercise capacity measured by the 6-minute walk test.

Secondary

MeasureTime frameDescription
Change in dietary behaviorsbaseline, 6-, 12-, and 24-monthsChange in dietary behaviors measured with the Block Food Frequency Questionnaire (FFQ)21 and the Questionnaire on Eating and Weight Patterns (QEWP).
Change in stage of changebaseline, 6-, 12-, and 24-monthsChange in stage of change measured with the Weight Loss Behavior-Stage of Change Scale (WLB-SOC) 23 to assess stage of change for engaging in healthy eating and exercise behaviors.
Change in eating behaviorbaseline, 6-, 12-, and 24-monthsChange in eating behavior measured with the Dutch Eating Behavior Questionnaire which includes 13 questions assessing emotional eating and 10 questions related to external eating behaviors
Change in physical measurementbaseline, 6-, 12-, and 24-monthsIncluding height, weight, pulse, CO2 level, lung capacity from spirometer, variables from impedance measure such as percentage of body fat and percentage of lean muscle mass, cholesterol and triglyceride levels from finger stick (cholesterol data for data points that have already passed will be collected from participants' clinic and hospital records), waist circumference: BMI derived from height and weight.
Change in smoking and substance usebaseline, 6-, 12-, and 24-monthsChange in smoking and substance use measured by questions developed for R01DA021245, Smoking Cessation and Smoking Relapse Prevention in Patients with Schizophrenia, and questions from the Quit Smoking Decision Aid( developed by Ferron and Brunette, CPHS # 180) to ascertain smoking frequency, quantity, and cessation attempts
Change in psychological functioning (depression, negative symptoms, and self-efficacy).baseline, 6-, 12-, and 24-monthsChange in psychological functioning measured by the Center for Epidemiologic Studies Depression Scale,Scale to Assess Negative Symptoms,16 and the Self-Rated Abilities for Health Practices Scale will be used to assess these constructs.
Self-reported physical activitybaseline, 6-, 12-, and 24-monthsChange in self-reported physical activity measured with International Physical Activity Questionnaire (IPAQ)
Change in family contactbaseline, 6-, 12-, and 24-monthsChange in family contact measured by the Revised Family Contact Questionnaire.
Change in social support and eating habitsbaseline, 6-, 12-, and 24-monthsChange in the impact of social support on eating habits measured by the Social Support and Eating Habits Survey
Change in social support and exercisebaseline, 6-, 12-, and 24-monthsChange in the impact of social support on exercise behaviors measured by the Social Support and Exercise Survey
Change in comorbid medical illnessbaseline, 6-, 12-, and 24-monthsChange in comorbid medical illness measured using a medical problems list.
Change in medicationsbaseline, 6-, 12-, and 24-monthsChange in medications measured by gathering information from participants about type, dose, and frequency of all prescribed medications.
Change in service usebaseline, 6-, 12-, and 24-monthsMeasured change in service use based on a measured designed for the In SHAPE studies to collect self-reported use of emergency services and hospitalizations.
Change in social functioningbaseline, 6-, 12-, and 24-monthsChange in social functioning measured by the Social Network Questionnaire and Lehman Social Contact Scale.

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026